|本期目录/Table of Contents|

[1]彭 惠,申恩瑞,马世武.吡嗪酰胺诱导的高尿酸血症[J].传染病信息,2018,04:376-379.
 PENG Hui,SHEN En-rui,MA Shi-wu*.Pyrazinamide-induced hyperuricemia[J].Infectious Disease Information,2018,04:376-379.



综  述


Pyrazinamide-induced hyperuricemia
彭 惠申恩瑞马世武
650223,成都军区昆明总医院感染科(彭惠、马世武); 650223,成都军区昆明总医院临床学院(彭惠);654300 红河哈 尼族彝族自治州,建水县人民医院感染科(申恩瑞)
PENG Hui SHEN En-rui MA Shi-wu*
Department of Infectious Diseases, Kunming General Hospital of Chengdu Military Command, 650223, China
tuberculosis hyperuricemia pyrazinamide renal insufficiency diabetes mellitus
吡嗪酰胺诱导的高尿酸血症(pyrazinamide-induced hyperuricemia, PIHU)主要发生于抗结核治疗的强化期,在 临床的发生率高,患者多无明显症状,因此防治PIHU 容易被临床忽视。然而,随着结核病耐药形势愈趋严重,吡嗪酰胺在 临床的应用更加广泛及长程(4 ~ 20 个月),使得PIHU 对治疗方案的制定及执行的影响愈显突出。我们针对上述问题, 对PIHU 的流行、发病机制、转归、防治等展开分析,特别针对特殊结核患者的PIHU 进行了阐述,以引发更多关于PIHU 的临床思考,为合理防治PIHU 提供理论依据。
The pyrazinamide-induced hyperuricemia (PIHU) is prevalent during first two months (enhanced stage) of antituberculosis treatment, with a high incidence rate. Since PIHU is usually asymptomatic, the prevention and treatment of PIHU are easily overlooked in clinical practice. However, with the growing incidence of drug-resistant tuberculosis, pyrazinamide has been widely used in clinical treatment of drug-resistant tuberculosis, and the course of treatment is also prolonging (4-20 months), which makes PIHU display in a prominant position on the formation and implement of treatment scheme. Therefore, we analyzes the epidemiology, pathogenesis, outcome, prevention and treatment of PIHU, and particularly elucidate PIHU in some special patients with tuberculosis, with the expectation of arousing more clinical thought on PIHU, and provide further theory basis for prevention and treatment of PIHU.


[1] World Health Organization. Global tuberculosis report 2016 [EB/ OL]. [2017-10-16]. http://www.who.int/tb/publications/global_ report/en/.
[2] World Health Organization. Treatment of tuberculosis: guidelines [EB/OL]. [2017-10-16]. http://apps.who.int/iris/bitstre am/10665/44165/1/9789241547833_eng.pdf?ua=1&ua=1.
[3] Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population[J]. Arthritis Rheum, 2011, 63:3136–3141.
[4] World Health Organization. Guidelines for tuberculosis treatment in adults and children in national tuberculosis programmes[EB/OL]. [2017-10-16]. http://apps.who.int/iris/ bitstream/10665/59121/1/WHO_TB_91.161.pdf.
[5] 中华医学会结核病学分会. 肺结核诊断和治疗指南[J]. 中 华结核和呼吸杂志,2001,24(2):70-74.
[6] 胡越凯,卢洪洲. 耐药结核病的药物选择[J]. 传染病信息, 2014,27(3):139-142.
[7] 中国医师协会心血管内科医师分会. 无症状高尿酸血症合并 心血管疾病诊治建议中国专家共识[J]. 中国医学前沿杂志 电子版,2010,16(3):253-256.
[8] Ichida K, Hosoyamada M, Kimura H, et al. Urate transport via human PAH transporter hOAT1 and its gene structure[J]. Kidney Int, 2003, 63(1):143-155.
[9] Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels[J]. Nature, 2002, 417(6887):447-452.
[10] Lv X, Tang S, Xia Y, et al. Adverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients: a prospective study[J]. PLoS One, 2013, 8(6):e65037.
[11] 袁进,梁虹艺,石磊. 吡嗪酰胺抗结核化疗致高尿酸血症流 行病学调查[J]. 药物流行病学杂志,2012,21(2):78-80.
[12] 郑兰,汪洁,钟辉,等. 吡嗪酰胺抗结核治疗前后血尿酸 水平变化的相关性研究[J]. 临床合理用药杂志,2012, 5(8):1-3.
[13] Taki H, Ogawa K, Murakami T, et al. Epidemiological survey of hyperuricemia as an adverse reaction to antituberculous therapy with pyrazinamide[J]. Kekkaku, 2008, 83(7):497-501.
[14] Qureshi W, Hassan G, Kadri SM, et al. Hyperuricemia and arthralgias during pyrazinamide therapy in patients with pulmonary tuberculosis[J]. Laboratory Medicine, 2007, 38(8):495-497.
[15] Farazi A, Sofian M, Jabbariasl M, et al. Adverse reactions to antituberculosis drugs in Iranian tuberculosis patients[J]. Tuberc Res Treat, 2014, 2014: 412893.
[16] Pokam BD, Eeteneneng EJ, Umoh A, et al. Uric acid levels in patients on antituberculosis drugs in the Southwest region of Cameroon[J]. Int J Mycobacteriol, 2016, 5(Suppl 1):S116.
[17] Gulbay BE, Gurkan OU, Yildiz OA, et al. Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis[J]. Respir Med, 2006, 100(10):1834-1842.
[18] Solangi GA, Zuberi BF, Shaikh S, et al. Pyrazinamide induced hyperuricemia in patients taking anti-tuberculous therapy[J]. J Coll Physicians Surg Pak, 2004, 14(3):136-138.
[19] Vieira DE, Gomes M. Adverse effects of tuberculosis treatment: experience at an outpatient clinic of a teaching hospital in the city of Sao Paulo, Brazil[J]. J Bras Pneumol, 2008, 34(12):1049- 1055.
[20] Shin SS, Pasechnikov AD, Gelmanova IY, et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia[J]. Int J Tuberc Lung Dis, 2007, 11(12):1314-1320.
[21] Adebisi SA, Oluboyo PO, Okesina AB. Effect of drug-induced hyperuricaemia on renal function in Nigerians with pulmonary tuberculosis[J]. Afr J Med Med Sci, 2000, 29(3-4):297-300.
[22] Sanchez-Albisua I, Vidal ML, Joya-Verde G, et al. Tolerance of pyrazinamide in short course chemotherapy for pulmonary tuberculosis in children[J]. Pediatr Infect Dis J, 1997, 16(8):760-763.
[23] Chang HJ, Wang PC, Hsu YC, et al. Gout with auricular tophi following anti-tuberculosis treatment: a case report[J]. BMC Res Notes, 2013, 6:480.
[24] Campion EW, Glynn RJ, Delabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study[J]. Am J Med, 1987, 82(3):421-426.
[25] Gupta S, Gupta V, Kapoor B, et al. Pyrazinamide induced hyperuricaemia presenting as severe bilateral leg cramps[J]. J Indian Med Assoc, 2007, 105(6):341-342.
[26] Namba S, Igari T, Nishiyama K, et al. A case of pyrazinamideassociated myoglobinuric renal failure[J]. Jpn J Med, 1991, 30(5):468-472.
[27] Sanwikarja S, Kauffmann RH, Te Velde J, et al. Tubulointerstitial nephritis associated with pyrazinamide[J]. Neth J Med, 1989, 34(1-2):40-46.
[28] Pham AQ, Doan A, Andersen M. Pyrazinamide-induced hyperuricemia[J]. P T, 2014, 39(10):695-715.
[29] 中华医学会风湿病学分会. 2016 中国痛风诊疗指南[J]. 中 华内科杂志, 2016,55(11):892-899.
[30] Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis[J]. Arthritis Care Res (Hoboken), 2012, 64(10):1447-1461.
[31] Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia[J]. Arthritis Care Res (Hoboken), 2012, 64(10):1431-1446.
[32] 中华医师协会肾脏内科分会. 中国肾脏疾病高尿酸血症诊 治的实践指南(2017 版)[J]. 中华医学杂志, 2017, 97(25):1927-1936.
[33] Jansen TL, Reinders MK, van Roon EN, et al. Benzbromarone withdrawn from the European market: another case of “absence of evidence is evidence of absence”?[J]. Clin Exp Rheumatol, 2004, 22(5):651.
[34] Lee MH, Graham GG, Williams KM, et al. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?[J]. Drug Saf, 2008, 31(8):643–665.
[35] Gerdan V, Akkoc N, Ucan ES, et al. Paradoxical increase in uric acid level with allopurinol use in pyrazinamide-induced hyperuricaemia[J]. Singapore Med J, 2013, 54(6):e125-e126.
[36] Pession A, Melchionda F, Castellini C. Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase)[J]. Biologics, 2008, 2(1):129-141.
[37] Cammalleri L, Malaguarnera M. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout[J]. Int J Med Sci, 2007, 4(2):83-93.
[38] Pichholiya M, Yadav AK, Luhadia SK, et al. A comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamideinduced hyperuricemic tubercular patients[J]. Indian J Pharmacol, 2016, 48(5):522-525.
[39] Jeong HK, Lee KJ, Yoon W, et al. Unusual presentation of gouty spondylitis following antituberculosis therapy[J]. Clin Exp Rheumatol, 2008, 26(3):507. 传染病信息 2018 年8 月30 日 第31 卷 第4 ·380· 期 Infect Dis Info, Vol. 31, No. 4, August 30, 2018
[40] Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis[J]. Am J Respir Crit Care Med, 2003,167(4):603-662.
[41] Igari H, Imasawa T, Noguchi N, et al. Advanced stage of chronic kidney disease is risk of poor treatment outcome for smearpositive pulmonary tuberculosis[J]. J Infect Chemother, 2015, 21(8):559-563.
[42] Milburn H, Ashman N, Davies P, et al. Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease[J]. Thorax, 2010, 65(6):557-570.
[43] Yang L, Shao J, Bian Y, et al. Prevalence of type 2 diabetes mellitus among inland residents in China (2000-2014): a meta-analysis[J]. J Diabetes Investig, 2016, 7(6):845-852.
[44] Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies[J]. PLoS Med, 2008, 5:e152.
[45] 陈红光,刘民,顾芳慧. 中国大陆地区肺结核合并糖尿 病患病率的Meta 分析[J]. 中华流行病学杂志,2013, 34(11):1128-1133.
[46] Mantovani A, Rigolon R, Pichiri I, et al. Hyperuricemia is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes[J]. J Endocrinol Invest, 2016, 39(2):159-167.
[47] 王黎霞,成诗明,陈明亭,等. 2010 年全国第五次结核病流 行病学抽样调查报告[J]. 中国防痨杂志,2012,34(8):485- 508.
[48] Schils R, Krzesinski JM. Hyperuricemia and potential risk of cardiovascular and renal diseases[J]. Rev Med Liege, 2016, 71(5):262-268.
[49] Kim S Y, Guevara JP, Kim KM, et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis[J]. Arthritis Rheum, 2009, 61(7):885-892. [50] 杨军,魏敏. 2 种化疗方案治疗老年初治肺结核的疗效和安全 性研究[J]. 传染病信息,2016,29(5):291-294.


[ 基金项目 ] 云南省中青年学术技术带头人项目(第十八批);全 军后勤科研计划面上项目(CCD14C004) [ 作者单位 ] 650223,成都军区昆明总医院感染科(彭惠、马世武); 650223,成都军区昆明总医院临床学院(彭惠);654300 红河哈 尼族彝族自治州,建水县人民医院感染科(申恩瑞) [ 通信作者 ] 马世武,E-mail: mashiwu@hotmail.com
更新日期/Last Update: 2018-09-08